CUTANEOUS T-CELL LYMPHOMA STAGE III

CUTANEOUS T-CELL LYMPHOMA STAGE III was reported 23 times

CUTANEOUS T-CELL LYMPHOMA STAGE III is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-17A Antagonist [EPC] 3 0.0001
1 Purine Antimetabolite [EPC] 5 0.0001
2 Calcineurin Inhibitor Immunosuppressant [EPC] 6 0.0000
3 beta3-Adrenergic Agonist [EPC] 2 0.0000
4 Interleukin-23 Antagonist [EPC] 4 0.0000
5 Anti-IgE [EPC] 3 0.0000
6 Interleukin-12 Antagonist [EPC] 3 0.0000
7 Interleukin-4 Receptor alpha Antagonist [EPC] 14 0.0000
8 Folate Analog Metabolic Inhibitor [EPC] 6 0.0000
9 Phosphodiesterase 4 Inhibitor [EPC] 2 0.0000
10 Retinoid [EPC] 3 0.0000
11 Alkylating Drug [EPC] 2 0.0000
12 Janus Kinase Inhibitor [EPC] 1 0.0000
13 Vitamin D [EPC] 1 0.0000
14 Vitamin B12 [EPC] 1 0.0000
15 Tumor Necrosis Factor Blocker [EPC] 3 0.0000
16 Vitamin C [EPC] 1 0.0000
17 Loop Diuretic [EPC] 1 0.0000
18 Corticosteroid [EPC] 2 0.0000
19 Nonsteroidal Anti-inflammatory Drug [EPC] 1 0.0000